# Noboru Yamamoto

Source: https://onco.cc/people/yamamoto-noboru/  
OnCo record `yamamoto-noboru` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs Japan's largest first-in-human oncology unit, where many Daiichi Sankyo DXd ADCs were first given to patients.

## Summary

Noboru Yamamoto is Director of the Department of Experimental Therapeutics at the National Cancer Center Hospital in Tokyo. He runs Japan's largest first-in-human oncology unit, where many of the Daiichi Sankyo DXd antibody-drug conjugates were first given to patients, including trastuzumab deruxtecan and datopotamab deruxtecan. His publications include the TROPION-PanTumor01 first-in-human study of datopotamab deruxtecan in non-small-cell lung cancer, the REMORA phase 2 trial of lenvatinib in advanced thymic carcinoma, and a phase 1 study of the anti-CCR4 antibody mogamulizumab combined with nivolumab in solid tumours. His interests are phase 1 trials, drug development and lung cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Department of Experimental Therapeutics, National Cancer Center Hospital
- Specialisms: Phase 1 trials; Drug development; Lung cancer; Antibody-drug conjugates

## Sources

- National Cancer Center Hospital: https://www.ncc.go.jp/en/ncch/index.html
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Yamamoto%20N%5BAuthor%5D%20National%20Cancer%20Center%20phase%201

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- institutions: [National Cancer Center Hospital](https://onco.cc/institutions/ncc-japan/)

---
JSON: https://onco.cc/api/v1/entities/yamamoto-noboru.json